Advertisement

Rheumatology International

, Volume 34, Issue 3, pp 315–320 | Cite as

Osteoarthritis pain has a significant neuropathic component: an exploratory in vivo patient model

  • Rui V. DuarteEmail author
  • Jon H. Raphael
  • Theodoros Dimitroulas
  • Elizabeth Sparkes
  • Jane L. Southall
  • Robert L. Ashford
  • George D. Kitas
Original Article

Abstract

Osteoarthritis is the most common form of arthritis and includes manifestations of both nociceptive and neuropathic mechanisms. Intravenous lignocaine, a sodium channel blocker and neuronal membrane stabiliser, has been shown in controlled trials to be effective in neuropathic pain; however, the outcome of intravenous lignocaine in osteoarthritis patients has not been assessed yet. The existence of a neuropathic component to the pain of osteoarthritis was investigated by examining possible benefits upon sensory aspects of pain in osteoarthritis patients receiving intravenous lignocaine therapy. Retrospective observational study was carried out using health data routinely collected for non-research purposes. Patients with generalised osteoarthritis who had not responded to more conservative treatments were recruited sequentially and scheduled for intravenous lignocaine therapy either in the rheumatology or pain relief departments. Assessment of efficacy was carried out through a questionnaire including sensory, psychological and social aspects of pain. The sample consisted of 17 women (60.7 %) and 11 men (39.3 %) with an average age at the time of treatment of 59 ± 11 years. The average pain relief calculated from the NRS scores was 30.2 ± 21.4 %, and the mean duration of pain relief was 10 ± 6 weeks. Pain intensity (p < 0.001), pain relief (p < 0.003) and mobility (p < 0.003) were all significantly improved after administration of lignocaine intravenous infusion therapy. Pain was significantly reduced in a group of osteoarthritis patients after administration of intravenous lignocaine. This suggests that part of the pain mechanism in this patient group may be neuropathic, appears to contribute significantly to the patients’ pain, and requires further investigation in studies designed specifically for the purpose.

Keywords

Osteoarthritis Pain intensity Intravenous lignocaine Neuropathic pain 

Notes

Acknowledgments

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

References

  1. 1.
    Arden N, Nevitt MC (2006) Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol 20(1):3–25PubMedCrossRefGoogle Scholar
  2. 2.
    Felson DT (2005) Relation of obesity and of vocational and avocational risk factors to osteoarthritis. J Rheumatol 32(6):1133–1135PubMedGoogle Scholar
  3. 3.
    Dray A, Read SJ (2007) Arthritis and pain. Future targets to control osteoarthritis pain. Arthritis Res Ther 9(3):212PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Bjordal JM, Ljunggren AE, Klovning A, Slørdal L (2004) Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 329(7478):1317PubMedCrossRefGoogle Scholar
  5. 5.
    Neame R, Zhang W, Doherty M (2004) A historic issue of the annals: three papers examine paracetamol in osteoarthritis. Ann Rheum Dis 63(8):897–900PubMedCrossRefGoogle Scholar
  6. 6.
    Catterall WA (2002) Molecular mechanisms of gating and drug block of sodium channels. Novartis Found Symp 241:206–218PubMedCrossRefGoogle Scholar
  7. 7.
    Kastrup J, Petersen P, Dejgård A, Angelo HR, Hilsted J (1987) Intravenous lidocaine infusion: a new treatment of chronic painful diabetic neuropathy? Pain 28(1):69–75PubMedCrossRefGoogle Scholar
  8. 8.
    Rowbotham MC, Reisner-Keller LA, Fields HL (1991) Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 41(7):1024–1028PubMedCrossRefGoogle Scholar
  9. 9.
    Mao J, Chen LL (2000) Systemic lidocaine for neuropathic pain relief. Pain 87(1):7–17PubMedCrossRefGoogle Scholar
  10. 10.
    Burch F, Codding C, Patel N, Sheldon E (2004) Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients. A prospective, multicenter, open-label effectiveness trial. Osteoarthr Cartil 12(3):253–255PubMedCrossRefGoogle Scholar
  11. 11.
    Gammaitoni AR, Galer BS, Onawola R, Jensen MP, Argoff CE (2004) Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the neuropathic pain scale. Curr Med Res Opin 20(suppl 2):S13–S19PubMedCrossRefGoogle Scholar
  12. 12.
    Loughnan TE, Taverner MG, Webb A (2009) Randomized, double blinded comparative trial of intradermal injections of lignocaine versus N-saline around the knee to relieve pain in patients awaiting total knee replacement. Clin J Pain 25(4):269–272PubMedCrossRefGoogle Scholar
  13. 13.
    Altman RD (1991) Criteria for classification of clinical osteoarthritis. J Rheumatol Suppl 27:10–12PubMedGoogle Scholar
  14. 14.
    Raphael JH, Southall JL, Kitas GD (2003) Adverse effects of intravenous lignocaine therapy in fibromyalgia syndrome. Rheumatology 42(1):185–186PubMedCrossRefGoogle Scholar
  15. 15.
    Dworkin RH, Turk DC, Farrar JT et al (2005) Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113(1–2):9–19PubMedCrossRefGoogle Scholar
  16. 16.
    Cohen J (1992) A power primer. Psychol Bull 112(1):155–159PubMedCrossRefGoogle Scholar
  17. 17.
    Dworkin RH, Turk DC, Wyrwich KW et al (2008) Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9(2):105–121PubMedCrossRefGoogle Scholar
  18. 18.
    Koppert W, Zeck S, Sittl R, Likar R, Knoll R, Schmelz M (1998) Low-dose lidocaine suppresses experimentally induced hyperalgesia in humans. Anesthesiology 89(6):1345–1353PubMedCrossRefGoogle Scholar
  19. 19.
    Koppert W, Ostermeier N, Sittl R, Weidner C, Schmelz M (2000) Low-dose lidocaine reduces secondary hyperalgesia by a central mode of action. Pain 85(1–2):217–224PubMedCrossRefGoogle Scholar
  20. 20.
    Dray A (2008) New horizons in pharmacologic treatment for rheumatic disease pain. Rheum Dis Clin N Am 34(2):481–505CrossRefGoogle Scholar
  21. 21.
    Hochman JR, French MR, Bermingham SL, Hawker GA (2010) The nerve of osteoarthritis pain. Arthrit Care Res 62(7):1019–1023CrossRefGoogle Scholar
  22. 22.
    Im H, Kim J, Li X et al (2010) Alteration of sensory neurons and spinal response to an experimental osteoarthritis pain model. Arthritis Rheum 62(10):2995–3005PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Zhang W, Doherty M, Leeb BF et al (2007) EULAR evidence based recommendations for the management of hand osteoarthritis: report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 66(3):377–388PubMedCrossRefGoogle Scholar
  24. 24.
    Felson DT, Lawrence RC, Hochberg MC et al (2000) Osteoarthritis: new insights. Part 2: treatment approaches. Ann Intern Med 133(9):726–737PubMedCrossRefGoogle Scholar
  25. 25.
    Wandel S, Jüni P, Tendal B et al (2010) Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 341:c4675PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Hawker GA (2009) Experiencing painful osteoarthritis: what have we learned from listening? Curr Opin Rheumatol 21(5):507–512PubMedCrossRefGoogle Scholar
  27. 27.
    Rosemann T, Laux G, Szecsenyi J, Wensing M, Grol R (2008) Pain and osteoarthritis in primary care: factors associated with pain perception in a sample of 1,021 patients. Pain Med 9(7):903–910PubMedCrossRefGoogle Scholar
  28. 28.
    Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M (2008) The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis 67(12):1716–1723PubMedCrossRefGoogle Scholar
  29. 29.
    Raphael JH, Southall JL, Treharne GJ, Kitas GD (2002) Efficacy and adverse effects of intravenous lignocaine therapy in fibromyalgia syndrome. BMC Musculoskelet Disord 3:21PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Rui V. Duarte
    • 1
    • 2
    Email author
  • Jon H. Raphael
    • 1
    • 2
  • Theodoros Dimitroulas
    • 3
  • Elizabeth Sparkes
    • 4
  • Jane L. Southall
    • 2
  • Robert L. Ashford
    • 1
  • George D. Kitas
    • 3
  1. 1.Faculty of Health, Centre for Health and Social Care ResearchBirmingham City UniversityBirminghamUK
  2. 2.Department of Pain ManagementRussells Hall HospitalDudleyUK
  3. 3.Department of RheumatologyRussells Hall HospitalDudleyUK
  4. 4.Department of Psychology and Behavioural SciencesCoventry UniversityCoventryUK

Personalised recommendations